- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05280106
Citrate Dialysate in Online Hemodialfiltration
February 3, 2023 updated by: Thananda Trakarnvanich, Bangkok Metropolitan Administration Medical College and Vajira Hospital
Comparison of Citrate Dialysate in Predilution and Postdilution Online Hemodiafiltration : Effect on Clot Formation and Adequacy of Dialysis in Hemodialysis Patients
Online hemodiafiltration (Ol-HDF) is increasingly being used for patients on chronic dialysis due to in its superiority compared with standard hemodialysis HDF.
In addition to an excellent clearance of small molecules, oL-HDF has more advantages by providing both diffusion and convection modalities for an additional clearance of medium-size molecules.
Furthermore, OL-HDF has been associated with not only better hemodynamic tolerance and biocompatibility , but may even include better survival.with
reduction of proinflammatory cytokines and proinflammatory circulating cells , as well as with better control of B2MG levels .Ol-HDF is classified into 2 types according to the mode of addition of the substitution fluid: pre-dilution OL-HDF (pre-HDF) and post-dilution OL-HDF (post-HDF); Post-HDF was associated with significantly higher removal rates of β2-MG than HD.
Postdilution HDF is the most effective way to maximize molecule clearance .Post-HDF was associated with significantly higher removal rate of α1-MG, and also significantly higher albumin leakage, than HD and pre-HDF.
However, blood concentrations can be elevated using HDF, which can cause thrombosis.
On the other hand, predilution HDF can resolve this problem but requires about three times more purified water than postdilution HDF and may not elicit maximal clearance.
Study Overview
Status
Completed
Conditions
Detailed Description
Heparin is the most routinely used anticoagulant in hemodialysis.
However, it exposes the patient to the risk of bleeding complications and can induce thrombocytopenia.
Furthermore, long-term use of heparin induces biological and clinical complications (osteoporosis, dyslipidemia, hyperkalemia) .
Regional citrate anticoagulation is a good alternative to heparin use in hemodialysis for patients with increased bleeding risk , but its implementation in bicarbonate hemodialysis (BHD) is laborious and cumbersome: severe side effects can occur due to citrate metabolism and difficulties in adaptation of calcium infusion into the venous line .Therefore, the use of citrate as a dialysis buffer instead of acetate has proven a safe alternative to acetate-containing bicarbonate dialysis and on-line hemodiafiltration without significant hypocalcemia or clinically important coagulation issues.The aim of the present study is the comparison of the patency of the dialyzer ,the quality of life and blood parameters between pre and potdiltuiotn Ol-HDF with citrate dialysate (CD).
No study to date has previously compared the use of citrate dialysate between these two modalities in oL-HDF.
Study Type
Interventional
Enrollment (Actual)
9
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bangkok, Thailand, 10300
- Faculty of Medicine ,Vajira Hospital
-
Bangkok, Thailand, 10300
- Faculty of Medicine ,Vajira hospital,Navamindradhiraj University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Stable condition
- Having been under HD for at least three months
- he vascular access should have blood flow ≥ 300 mL/min.
Exclusion Criteria:
- no heparin use during HD
- refusal to participate,
- intolerance or allergy to citrate
- concurrent infection
- poor life expectancy due to metastatic cancer, severe cirrhosis and AIDS.
- patients vascular access modification,
- patients affected by chronic liver disease, active neoplastic or inflammatory disease were excluded as well as patients receiving immunosuppressive or anti-inflammatory drugs.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Pre-dilution online hemodiafiltration
The study was conducted for a 28-week period in two phases: For the first 12 weeks, all of the patients were subjected to CD with pre-dilution oL-HDF.After enrollment, all patients began a 2-week run-in period with conventional dialysis fluid containing acetate and the lowest dose of unfractionated heparin.
The investigator titrated the heparin dose by reducing the dose step by step, 25% in each step, until the final minimal dose was achieved.
The experimental study consisted of 3 phases, 4 weeks in each phase, and the phases were separated by 1-week washout periods.
The second phase will run after finishing the first phase with the same protocol but with post-dilution online HDF.There will be 2 weeks washout period before starting this phase
|
After enrollment, all patients began a 2-week run-in period with conventional dialysis fluid containing acetate and the lowest dose of unfractionated heparin.
The investigator titrated the heparin dose by reducing the dose step by step, 25% in each step, until the final minimal dose was achieved.
The experimental study consisted of 3 phases, 4 weeks in each phase, and the phases were separated by 1-week washout periods.
Phase 1 used CD with 50% of the heparin dose of the baseline.
Phases 2 and 3 used 25% heparin and no heparin, respectively.
New dialyzers were introduced at the beginning of each phase and the heparin dose was resumed during the washout phase.
The calcium concentration in the dialysis fluid was kept constant (1.5 mmol/L) to allow evaluation of the effect of CD on calcium balance
same protocol with post-dilution Ol-HDF in these same patients for the later 12 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
clotting score between pre and post dilution online-hemodiafiltration
Time Frame: 28 weeks
|
5 grades of clotting score, Grade 1;No or very little residual blood in the filters.Grade 1;Residual blood in less than 10% of the fibers.
Grade 2; Residual blood 10-25%.
Grade 3; Residual blood 25-50%.Grade 4 ,Residual blood > 50%
|
28 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
quality of life between pre and post dilution online-hemodiafiltration
Time Frame: 28 weeks
|
KDQOL-sf score;0-100.Higher scores reflect better quality of life
|
28 weeks
|
adequacy of dialysis between pre and post dilution online-hemodiafiltration
Time Frame: 28 weeks
|
Kt/V
|
28 weeks
|
calcium level between pre and post dilution online-hemodiafiltration
Time Frame: 28 weeks
|
serum calcium predialysis in midweek of each phase
|
28 weeks
|
phosphorus level between pre and post dilution online-hemodiafiltration
Time Frame: 28 weeks
|
serum calcium predialysis in midweek of each phase
|
28 weeks
|
intact parathyroid level between pre and post dilution online-hemodiafiltration
Time Frame: 28 weeks
|
serum parathyroid level in midweek of each phase
|
28 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Carracedo J, Merino A, Nogueras S, Carretero D, Berdud I, Ramirez R, Tetta C, Rodriguez M, Martin-Malo A, Aljama P. On-line hemodiafiltration reduces the proinflammatory CD14+CD16+ monocyte-derived dendritic cells: A prospective, crossover study. J Am Soc Nephrol. 2006 Aug;17(8):2315-21. doi: 10.1681/ASN.2006020105. Epub 2006 Jul 6.
- Thaweethamcharoen T, Srimongkol W, Noparatayaporn P, Jariyayothin P, Sukthinthai N, Aiyasanon N, Kitisriworapan P, Jantarakana K, Vasuvattakul S. Validity and Reliability of KDQOL-36 in Thai Kidney Disease Patient. Value Health Reg Issues. 2013 May;2(1):98-102. doi: 10.1016/j.vhri.2013.02.011. Epub 2013 Mar 26.
- Canaud B, Bosc JY, Leray H, Stec F, Argiles A, Leblanc M, Mion C. On-line haemodiafiltration: state of the art. Nephrol Dial Transplant. 1998;13 Suppl 5:3-11. doi: 10.1093/ndt/13.suppl_5.3.
- Canaud B, Bragg-Gresham JL, Marshall MR, Desmeules S, Gillespie BW, Depner T, Klassen P, Port FK. Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int. 2006 Jun;69(11):2087-93. doi: 10.1038/sj.ki.5000447.
- Guth HJ, Gruska S, Kraatz G. On-line production of ultrapure substitution fluid reduces TNF-alpha- and IL-6 release in patients on hemodiafiltration therapy. Int J Artif Organs. 2003 Mar;26(3):181-7. doi: 10.1177/039139880302600301.
- Canaud B, Wizemann V, Pizzarelli F, Greenwood R, Schultze G, Weber C, Falkenhagen D. Cellular interleukin-1 receptor antagonist production in patients receiving on-line haemodiafiltration therapy. Nephrol Dial Transplant. 2001 Nov;16(11):2181-7. doi: 10.1093/ndt/16.11.2181.
- Lin CL, Yang CW, Chiang CC, Chang CT, Huang CC. Long-term on-line hemodiafiltration reduces predialysis beta-2-microglobulin levels in chronic hemodialysis patients. Blood Purif. 2001;19(3):301-7. doi: 10.1159/000046958.
- Kurihara Y, Hosoya H, Kishihara R, Yoshinaga M, Iwadate Y, Yamauchi F, Saito T, Sakurai K. Comparison of the effects of pre-dilution and post-dilution online hemodiafiltration on the levels of inflammatory markers, lymphocytes, and platelets. J Artif Organs. 2022 Mar;25(1):59-65. doi: 10.1007/s10047-021-01281-5. Epub 2021 Jun 14.
- Tsuchida K, Minakuchi J. Clinical benefits of predilution on-line hemodiafiltration. Blood Purif. 2013;35 Suppl 1:18-22. doi: 10.1159/000346221. Epub 2013 Feb 25.
- Hottelart C, Achard JM, Moriniere P, Zoghbi F, Dieval J, Fournier A. Heparin-induced hyperkalemia in chronic hemodialysis patients: comparison of low molecular weight and unfractionated heparin. Artif Organs. 1998 Jul;22(7):614-7. doi: 10.1046/j.1525-1594.1998.06204.x.
- Aniort J, Petitclerc T, Creput C. Safe use of citric acid-based dialysate and heparin removal in postdilution online hemodiafiltration. Blood Purif. 2012;34(3-4):336-43. doi: 10.1159/000345342. Epub 2013 Jan 9.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
February 1, 2022
Primary Completion (ACTUAL)
September 30, 2022
Study Completion (ACTUAL)
September 30, 2022
Study Registration Dates
First Submitted
March 6, 2022
First Submitted That Met QC Criteria
March 6, 2022
First Posted (ACTUAL)
March 15, 2022
Study Record Updates
Last Update Posted (ACTUAL)
February 8, 2023
Last Update Submitted That Met QC Criteria
February 3, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 080/64
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Haemodialysis
-
University Hospital, BrestCompleted
-
University Hospital, GhentNissho Nipro EuropeCompleted
-
University Hospital, BrestUnknown
-
The Leeds Teaching Hospitals NHS TrustUnknownHaemodialysis ComplicationUnited Kingdom
-
Université de Reims Champagne-ArdenneNot yet recruitingHaemodialysis PatientsFrance
-
Bayburt UniversityActive, not recruitingHaemodialysis PatientsTurkey
-
Great Ormond Street Hospital for Children NHS Foundation...UnknownChildren | Haemodialysis | HaemodiafiltrationUnited Kingdom
-
University Medical Center GroningenMartini Hospital GroningenCompleted
-
Ospedale Regionale di LocarnoFondazione Ettore Balli LocarnoCompleted
Clinical Trials on Pre-dilution online hemodiafiltration with citrate dialysate
-
A. Manzoni HospitalCompleted
-
Centre hospitalier de l'Université de Montréal...RecruitingAcute Kidney InjuryCanada, Ireland
-
Universitaire Ziekenhuizen KU LeuvenNIPROCompletedHemodialysis ComplicationBelgium
-
Hospital Israelita Albert EinsteinRecruitingAcute Kidney InjuryBrazil